The episode focuses on the refinement of CLL therapy, moving away from traditional chemoimmunotherapy toward targeted ...

Opportunities in the Global Refractory Follicular Lymphoma Diagnostics Market include the growing need for MRD monitoring and liquid biopsies, driven by the rise in hematologic malignancies. The surge ...

Michael Wang, MD, highlights ASH 2025 data showing how continual innovation across targeted agents, cellular and immune ...

This article is authored by Dr Amrit Kaur Kaler, consultant, molecular pathology, Kokilaben Dhirubhai Ambani Hospitals, ...

PFS significantly higher with nivolumab, doxorubicin, vinblastine, and dacarbazine versus brentuximab vedotin-AVD.

Cervical lymphadenopathy presents a shared anatomic challenge for clinicians, yet it serves as the divergent starting point for two distinct therapeutic pathways: Hodgkin’s lymphoma (HL) and ...

CTD402, an allogeneic CAR T-cell therapy, is designed for immediate administration and targets relapsed/refractory T-ALL and ...

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Imviva Biotech's CTD402 to accelerate the ...

Overall, MajesTEC-3 signals a meaningful step forward for combination bispecific therapies in multiple myeloma, while ...

Interim Futility Analysis of MRD Clearance from the Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line (1L) Consolidation Large B-Cell Lymphoma (LBCL) Planned for ...

Chugai files regulatory application with MHLF for additional indication of Tecentriq to treat adjuvant therapy for MRD-positive bladder cancer: Tokyo Thursday, January 29, 2026, 0 ...

US FDA grants orphan drug designation to Imviva Biotech’s CTD402 for the treatment of T-cell leukaemia and lymphoma: Boston Friday, January 30, 2026, 17:00 Hrs [IST] Imviva Biot ...